- Home
- Companies
- north america
- immunotherapy
Show results for
Refine by
Immunotherapy Suppliers In North America
101 companies found
based inAlameda, CALIFORNIA (USA)
Fluxion delivers advanced solutions that transform complex cell-based and cell-free assays. Leading labs across the globe rely on Fluxion's instruments, kits, and lab services to research novel biology, accelerate drug discovery, and tailor ...
based inMountain View, CALIFORNIA (USA)
iPSCs- a revolutionary discovery with untapped potential. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells ...
based inFort Myers, FLORIDA (USA)
NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with ...
Histology, tissue staining using the latest in automated staining platforms, and digital pathology services form the foundation of a strong anatomic pathology program. Anatomic Pathology at NeoGenomics offers in-house comprehensive diagnostic ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases. Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx ...
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
Influenza (Target age 65+) and Influenza+ SARS-C0V-2 ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
Reliable Identification of SARS-CoV-2-Specific T-Cell Responses. T Cells Take the Lead in COVID-19. A deeper understanding of viral-specific T-cell responses to COVID-19 is needed to explore vaccine responses, long-term immunity, predict patients at ...
based inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce local-regional hyperthermic temperatures in tumor tissue, intended to increase the effectiveness of anticancer radiotherapy, chemotherapy and ...
based inCambridge, MASSACHUSETTS (USA)
The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against ...
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone CD4 and CD8, molecules on the ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
based inCambridge, MASSACHUSETTS (USA)
Foundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer. We’re an essential partner to patients, physicians, researchers, and biopharma ...
Discover tissue AND blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic ...
based inNew York, NEW YORK (USA)
Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and ...
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid ...
based inCharlottesville, VIRGINIA (USA)
LumaCyte is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary ...
based inPrinceton, NEW JERSEY (USA)
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation, technology and services. ...
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much ...
based inPrinceton, NEW YORK (USA)
We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...
UGN-301 is UroGen’s in-licensed anti-CTLA-4 antibody (zalifrelimab). UGN-201 is our proprietary formulation of imiquimod, a toll-like receptor 7 (TLR 7) agonist. When combined, these medicines stimulate both the innate (UGN-201) and adaptive ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Ditiocarb sodium (Sodium diethyldithiocarbamate) is an accelerator of the rate of copper cementation. Sodium diethyldithiocarbamate reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast ...
based inSherbrooke, QUEBEC (CANADA)
At Immune Biosolutions (IBio), we strongly believe that biologics can transform and save lives. Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies. We create ...
Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies. ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...